AOA Dx Joins BLOODPAC to Accelerate Early Detection of Ovarian Cancer with Liquid Biopsy Innovations
AOA Dx is excited to join the BLOODPAC Consortium, a public-private initiative dedicated to advancing liquid biopsy technologies for cancer detection. Through this partnership, AOA Dx will contribute its expertise in lipidomics and multi-omics to help establish standards for early detection assays, particularly in ovarian cancer. With a commitment to scientific collaboration, AOA Dx plans to share its research on gangliosides, lipids, and proteins, furthering the integration of liquid biopsy into clinical practice.